362-03-8

Basic information

• Product Name: 10-Phenothiazine propiocic acid
• Synonyms: 10-Phenothiazine propiocic acid;10H-Phenothiazine-10-propanoic acid;10H-Phenothiazine-10-propionic acid;3-(10H-Phenothiazine-10-yl)propionic acid;Phenothiazine-10-propionic Acid;3-(10-Phenothiazin-10-yl)propionic Acid;3-(Phenothiazin-10-yl)propanoic Acid;NSC 525721
• CAS NO: 362-03-8
• Molecular Formula: C₁₅H₁₃NO₂S
• Molecular Weight: 271.34
• EINECS: 421-260-5
• Product Categories: Aroamtics;Heterocycles;Intermediates;Sulfur & Selenium Compounds
• Mol File: 362-03-8.mol

Chemical Properties

• Boiling Point: 477°Cat760mmHg
• Flash Point: 242.3°C
• Appearance: /
• Density: 1.321g/cm³
• Vapor Pressure: 6.62E-10mmHg at 25°C
• Solubility: Ethyl Acetate, Methanol, Water
• CAS DataBase Reference: 10-Phenothiazine propiocic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 10-Phenothiazine propiocic acid(362-03-8)
• EPA Substance Registry System: 10-Phenothiazine propiocic acid(362-03-8)

Safety Data

• Hazard Codes: N
• Statements: 51/53
• Safety Statements: 24/25-61
• HazardClass: IRRITANT
• Hazardous Substances Data: 362-03-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
10-Phenothiazine propiocic acid is used as a reagent for the addition of Phenothiazine (P318040), a compound with significant applications in the pharmaceutical industry. Its role in the synthesis of Phenothiazine-based drugs makes it a valuable component in drug development and production.
Used in Chemical Synthesis:
10-Phenothiazine propiocic acid is utilized as a reagent in the chemical synthesis of various compounds, particularly those involving Phenothiazine. Its unique chemical properties allow it to contribute to the formation of new molecules with potential applications in different fields.
Used in Research and Development:
In the realm of research and development, 10-Phenothiazine propiocic acid serves as a key compound for exploring the properties and potential applications of Phenothiazine and its derivatives. Its use in this context aids in advancing scientific knowledge and the discovery of new compounds with beneficial properties.

InChI:InChI=1/C15H13NO2S/c17-15(18)9-10-16-11-5-1-3-7-13(11)19-14-8-4-2-6-12(14)16/h1-8H,9-10H2,(H,17,18)/p-1

Upstream product

• 92-84-2 10H-phenothiazine 
• 107943-89-5 β-(10-Phenothiazyl)propionic acid ethyl ester 
• 1698-80-2 10H-phenothiazine-10-propanenitrile 

Downstream Products

• 3023-04-9 3-phenothiazin-10-yl-N-(4-thiazol-2-ylsulfamoyl-phenyl)-propionamide 
• 2886-42-2 N-[4-(2,6-dimethyl-pyrimidin-4-ylsulfamoyl)-phenyl]-3-phenothiazin-10-yl-propionamide 
• 2886-41-1 N-[4-(3,4-dimethyl-isoxazol-5-ylsulfamoyl)-phenyl]-3-phenothiazin-10-yl-propionamide 
• 7045-65-0 tetra-O-benzoyl-2-(3-phenothiazin-10-yl-propionylamino)-β-D-2-deoxy-glucopyranose 
• 2765-58-4 3-phenothiazin-10-yl-N-(4-sulfamoyl-phenyl)-propionamide 
• 2889-05-6 N-(4-carbamimidoylsulfamoyl-phenyl)-3-phenothiazin-10-yl-propionamide 
• 2889-04-5 N-(4-acetylsulfamoyl-phenyl)-3-phenothiazin-10-yl-propionamide 
• 5909-59-1 10-(3-chloropropyl)-10H-phenothiazine 

Relevant articles and documents

Electrochemical primer extension for the detection of single nucleotide polymorphisms in the cardiomyopathy associated MYH7 gene

We report the labelling of dideoxy nucleotides (ddNTPs) for use in electrochemical array based primer extension for the detection of single nucleotide polymorphisms (SNPs). The results confirm the extension of the immobilised primers for each of the four ddNTPs, representing a significant advance in achieving a cost-effective platform for screening of disease-specific SNPs.

Synthesis and bio-evaluation of phenothiazine derivatives as new anti-tuberculosis agents

Abstract Two series of phenothiazine derivatives were designed and synthesized. All compounds were tested for anti-tuberculosis activities against Mycobacterium tuberculosis H37RV. In comparison with mother compound of chlorpromazine, compound 6e shows promising anti-tuberculosis activity and much less mammalian cell cytotoxicity, compound 6e merits to be further explored as new anti-tuberculosis agents.

Phenothiazine-based CaaX competitive inhibitors of human farnesyltransferase bearing a cysteine, methionine, serine or valine moiety as a new family of antitumoral compounds

A new family of CaaX competitive inhibitors of human farnesyltransferase based on phenothiazine and carbazole skeleton bearing a l-cysteine, l-methionine, l-serine or l-valine moiety was designed, synthesized and biologically evaluated. Phenothiazine derivatives proved to be more active than carbazole-based compounds. Phenothiazine 1b with cysteine residue was the most promising inhibitor of human farnesyltransferase in the current study.

Peptide chemistry applied to a new family of phenothiazine-containing inhibitors of human farnesyltransferase

Novel phenothiazine derivatives bearing an amino acid residue were synthesized via peptide chemistry, and evaluated for their inhibitory potential on human farnesyltransferase. The phenothiazine unit proved to be an important bulky unit in the structure o

Peptide chemistry applied to a new family of phenothiazine-containing inhibitors of human farnesyltransferase

Novel phenothiazine derivatives bearing an amino acid residue were synthesized via peptide chemistry, and evaluated for their inhibitory potential on human farnesyltransferase. The phenothiazine unit proved to be an important bulky unit in the structure o

New farnesyltransferase inhibitors in the phenothiazine series

The biological screening of the chemical library of our Organic Chemistry Department, carried out on an automated fluorescence-based FTase assay, allowed us to discover that a phenothiazine derivative (1d) was an inhibitor of farnesyltransferase. Three new series of human farnesyltransferase inhibitors, based on a phenothiazine scaffold, were synthesized with protein farnesyltransferase inhibition potencies in the low micromolar range. Ester derivative 9d was the most active compound in these series. Four synthesized compounds were evaluated for their antiproliferative activity on a NCI-60 cancer cell line panel. The modest results obtained in this preliminary investigation showed that mixing the phenothiazine and the 1,2,3-triazole motif in the structure of a single compound can lead to new scaffolds in the field of farnesyltransferase inhibitors.

FLUORESCENCE MODULATORS

The present invention relates to fluorescence lifetime modulators, conjugates comprising fluorescence lifetime modulators moieties and methods of making them. The present invention further relates to the use of the fluorescence lifetime modulators and conjugates comprising the fluorescence lifetime modulator moieties for measuring the activity and detection of enzymes and for the study of protein-protein and protein-ligand interactions.

Electrochromic compound

A compound for use in electrochromic devices. The compound includes (1) β-(10-phenothiazyl)propoxy phosphonic acid; (2) β-(10-phenothiazyl)propyl-phosphonic acid; and (3) β-(10-phenothiazyl)propionate phosphonic acid.

Design, synthesis, and evaluation of efflux substrate-metal chelator conjugates as potential antimicrobial agents

Maintaining a proper balance of metal concentrations is critical to the survival of bacteria. We have designed and synthesized a series of conjugates of metal chelators and efflux transporter substrates aimed at disrupting bacterial metal homeostasis to a

Electrical communication between glucose oxidase and electrodes mediated by phenothiazine-labeled poly(ethylene oxide) bonded to lysine residues on the enzyme surface

A series of glucose oxidase (GOx) hybrids (GOx-phenothiazine-labeled poly(ethylene oxide) (PT-PEO)) capable of direct electrical communication with electrodes is synthesized by covalently modifying PT-PEO to lysine residues on the enzyme surface. The length of the PEO chain and the number of PT groups are systematically altered. After the PT-PEO modification, all the hybrids maintain more than 50% of enzyme activity relative to that of native GOx, although loss of the activity becomes greater with increasing PEO chain length. The catalytic current, icat, is observed at a potential more positive than 0.55 V after the addition of glucose, due to the intramolecular electron transfer (ET) from reduced forms of flavin adenine dinucletide (FADH2/FADH) to PT+ that are electrogenerated at the electrode. The icat value increases with the number of PT groups, indicating that most of the modified PT groups act as mediators. The magnitude of the icat increase depends on the PEO chain length and reveals a maximum for PT-PEO with the molecular weight of 3000. In contrast, the icat is almost constant for GOx-2-(10-phenothiazyl)propionic acid (PT-PA) hybrids with more than two PT groups synthesized by covalently modifying PT-PA to surface lysines, indicating that only a few key PT groups function as mediators. The maximum rate constant (130 s-1) for the ET from FADH2/FADH to PT+ is obtained for the GOx hybrid modified with five PT-PEO groups with the molecular weight of 3000.